First AD

Second AD

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.

Factors When Weighing Intensive Chemotherapy vs Other Regimens in Secondary AML

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Updates in the Treatment of Secondary AML After the 2024 SOHO Annual Meeting

OncLive News Network®

John Theurer Cancer Center, Hackensack University Medical Center

Cancer Centers

Partner

The Diagnosis and Prevalence of Secondary AML

Defining Intensive Chemotherapy Fitness in AML

Long-Term Data for CPX-351 in Secondary AML

Dose Intensity and Sequencing of Intensive Chemotherapy in Secondary AML

Goals in the Treatment of Secondary AML

The Role of Genetic Profiling in Secondary AML